Centessa Pharmaceuticals PLC
NASDAQ:CNTA
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.92
17.2
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CNTA stock under the Base Case scenario is 2.27 USD. Compared to the current market price of 17 USD, Centessa Pharmaceuticals PLC is Overvalued by 87%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Centessa Pharmaceuticals PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CNTA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Centessa Pharmaceuticals PLC
Balance Sheet Decomposition
Centessa Pharmaceuticals PLC
Current Assets | 315.1m |
Cash & Short-Term Investments | 256.5m |
Receivables | 39.1m |
Other Current Assets | 19.4m |
Non-Current Assets | 45.2m |
PP&E | 13m |
Other Non-Current Assets | 32.2m |
Current Liabilities | 39.4m |
Accounts Payable | 11.8m |
Accrued Liabilities | 27.5m |
Other Current Liabilities | 112k |
Non-Current Liabilities | 84.6m |
Long-Term Debt | 75.7m |
Other Non-Current Liabilities | 8.9m |
Earnings Waterfall
Centessa Pharmaceuticals PLC
Revenue
|
6.9m
USD
|
Operating Expenses
|
-178.1m
USD
|
Operating Income
|
-171.3m
USD
|
Other Expenses
|
20.2m
USD
|
Net Income
|
-151.1m
USD
|
Free Cash Flow Analysis
Centessa Pharmaceuticals PLC
USD | |
Free Cash Flow | USD |
CNTA Profitability Score
Profitability Due Diligence
Centessa Pharmaceuticals PLC's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Centessa Pharmaceuticals PLC's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
CNTA Solvency Score
Solvency Due Diligence
Centessa Pharmaceuticals PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Centessa Pharmaceuticals PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CNTA Price Targets Summary
Centessa Pharmaceuticals PLC
According to Wall Street analysts, the average 1-year price target for CNTA is 26.67 USD with a low forecast of 19.19 USD and a high forecast of 36.75 USD.
Dividends
Current shareholder yield for CNTA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
CNTA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Centessa Pharmaceuticals Ltd. operates as pharmaceutical company that develops medicines. The company is headquartered in Altrincham, Cheshire and currently employs 90 full-time employees. The company went IPO on 2021-05-28. The firm's asset-centric programs range from discovery-stage to late-stage development and include diverse therapeutic areas such as oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology and nephrology. Its portfolio consists of approximately 16 conviction programs, including four programs evaluated in clinical trials and 12 additional preclinical programs. Centessa's clinical stage product candidates include Lixivaptan, SerpinPC, Imgatuzumab and ZF874. The firm's preclinical assets include ZF887, MGX292, CBS001, CBS004, LB1, LB2, Oral OX2R Agonist, Intranasal OX2R Agonist, Dual STAT3/5 Degrader, EGFR Ex20 Inhibitor, EGFR-C797S Inhibitor and EGFR Inhibitors. The firm's subsidiaries include ApcinteX, Capella BioScience, Janpix, LockBody, Morphogen-IX, Orexia Therapeutics, Palladio Biosciences, PearlRiver Bio, PegaOne and Z Factor.
Contact
IPO
Employees
Officers
The intrinsic value of one CNTA stock under the Base Case scenario is 2.27 USD.
Compared to the current market price of 17 USD, Centessa Pharmaceuticals PLC is Overvalued by 87%.